Effect of the Automatic Surveillance System on Surveillance Rate of Colorectal Postpolypectomy Patients
Condition(s) studied
Investigational drug(s) / intervention(s)
AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through by telephone .: An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients by telephone.
AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through message.: An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients through message.
Manually remind the patients: Medical staff remind patients manually .
Study summary
In this study, we proposed a prospective study about the effect of the automatic surveillance system on surveillance rate of colorectal postpolypectomy patients. The enrolled patients were divided into group A with intelligent surveillance system reminding though telephone and message, group B with intelligent surveillance system reminding though message, group C with manual reminder, and group D with natural state. The surveillance among the four groups were compared.
Eligibility
Primary outcome measure(s)
- On-time Surveillance Rate — From enrollment to study completion, assessed up to 3 years.
The numerator is the number of patients with on-time surveillance, and the denominator is the number of all colorectal postpolypectomy patients requiring surveillance.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Renmin Hospital of Wuhan University | Wuhan | Hubei |
More Renmin Hospital of Wuhan University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05894850 on ClinicalTrials.gov ↗ ← All trials in China